Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth/Aviron FluMist Pulmonary Safety Requires More Analysis - FDA Cmte.

Executive Summary

Approval of Wyeth/Aviron's intranasal flu vaccine FluMist will likely hinge on further analysis of the pulmonary safety data for the product and information about interactions with concurrent immunizations following a review by FDA's Vaccines & Related Biological Products Advisory Committee July 27.
Advertisement

Related Content

FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
FluMist 60,000-Patient Phase IV Safety Study To Be Conducted With Kaiser
FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune
FluMist Pharmacy Administration In 36 States Upon Approval – MedImmune
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
FluMist Comparison To Inactivated Vaccine Suggested By FDA Committee
FluMist Initial Indication May Exclude Patients Under Age Five
Flumist advisory committee
Aviron FluMist Initial Indication May Exclude Youngest Children, CEO Says
Kaiser FluMist Safety Data Analysis To Be Submitted To FDA By Year-End
Advertisement
UsernamePublicRestriction

Register

PS038275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel